Drug Information

Drug General Information
Drug ID
D08JBL
Former ID
DNCL002401
Drug Name
PF-03446962
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 2 [523946]
Company
Pfizer New York, NY
Target and Pathway
Target(s) Activin receptor-like kinase-1 Target Info Modulator [544182]
PANTHER Pathway TGF-beta signaling pathway
Pathway Interaction Database ALK1 pathway
ALK1 signaling events
References
Ref 523946ClinicalTrials.gov (NCT01620970) PF-03446962 in Relapsed or Refractory Urothelial Cancer. U.S. National Institutes of Health.
Ref 544182ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 2011 June 30; 117(26): 6999-7006.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.